Bruhn Suzanne Louise 4
4 · Travere Therapeutics, Inc. · Filed May 21, 2026
Research Summary
AI-generated summary of this filing
Travere (TVTX) Director Suzanne Bruhn Receives Stock Award
What Happened
Suzanne Bruhn, a director of Travere Therapeutics (TVTX), received a total of 16,000 shares on 2026-05-19: 4,000 shares and 12,000 derivative shares (both reported as awards) at $0.00 per share. The awards are automatic non-employee director grants under the company’s equity plan; total cash cost to the insider was $0.
Key Details
- Transaction date: 2026-05-19; Filing date: 2026-05-21 (filed within the SEC’s two-business-day Form 4 window).
- Grants: 4,000 shares (A) and 12,000 derivative shares (A), $0.00 per share. Total awarded = 16,000 shares.
- Shares owned after transaction: Not reported in the filing.
- Footnotes: F1 — automatic equity grant under the 2018 Equity Incentive Plan for non-employee directors; F2 — the equity award vests over a one-year period.
- Transaction code: A (award/grant).
Context
These are routine director compensation awards rather than open-market purchases or sales. Derivative awards that vest over time are common for non-employee directors and are primarily a compensation mechanism, not a direct buy or sell signal about the insider’s view of the stock.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-05-19+4,000→ 32,750 total - Award
Stock option (right to buy)
[F1][F2]2026-05-19+12,000→ 12,000 totalExercise: $42.26From: 2027-05-19Exp: 2036-05-19→ Common Stock (12,000 underlying)
Footnotes (2)
- [F1]Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
- [F2]The equity award vests over a one year period.